The expression of TBX21, HLX1, IFNG, RORC, IL17A, IL17F, IL22, GATA3, IL4, IL5, FOXP3, TGFB1, PRF1 in circulating CD4+ and CD8+ T-cells was not different, comparing untreated and natalizumab-treated MS (Table 1). Here, IL17F is linked to myeloid sarcoma.